Opinion

Video

Exploring Results from CAPItello-291 Trial

William J. Gradishar, MD, examines the impact of the CAPItello-291 phase III trial on NCCN breast cancer guidelines, comparing the investigated drug to other PI3K pathway inhibitors and discussing its potential to shape future treatment strategies.

  1. In November 2023, capivasertib received FDA approval for use in advanced hormone receptor-positive breast cancer based on the results from the CAPItello-291 phase III trial. How has capivasertib been integrated into the NCCN guidelines for breast cancer?
    1. What are your thoughts on sequencing of capivasertib use in the management of HR+ breast cancer?
  2. How does capivasertib compare to other PI3K pathway inhibitors alpelisib and inavolisib from safety and efficacy standpoints?
Related Videos
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
4 KOLs are featured in this series
Surbhi Sidana, MD, MBBS
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
1 KOL is featured in this series.
Screenshot of Susan Wescott, RPh, MBA
Related Content
Stethoscope chart graph data | Image Credit: © amazing studio - stock.adobe.com
October 30th 2024

Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL

Karen Jacobson-Sive
The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Managed Care Cast
October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi
Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.
health policy chart | Image credit: JOURNEY STUDIO7 - stock.adobe.com
October 30th 2024

Exploring the Complexities of Biosimilars and Interchangeability

Skylar Jeremias
A panel of industry experts discussed the complexities of biosimilars and interchangeability, emphasizing the challenges in adoption, the need for regulatory and legislative solutions, and the importance of education to combat misinformation.
Managed Care Cast logo
July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
HPV written in blocks | Image Credit: Iana Alter - stock.adobe.com
October 29th 2024

HPV 16 and 18 Linked to Ovarian Cancer Risk

Celeste Krewson
In a recent meta-analysis, the prevalence of human papillomavirus (HPV), especially types 16 and 18, was significantly increased among patients with ovarian cancer (OC) vs controls.
Gary Cooper, MD, PhD, on an image with AJMC contributor
October 29th 2024

The Importance of Early Diagnosis of Alzheimer Disease

Greg Cooper, MD, PhD
With new therapies available to treat early stages of Alzheimer disease, recognizing the symptoms earlier is increasingly important.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo